Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
Clinician-focused summary of statin prescribing across special populations: pregnancy, pediatrics, hepatic/renal impairment, older adults, and race-based pharmacogenomic considerations for ASCVD prevention.
Read clinical reviewA clinical reference for prescribers and pharmacists on managing statin adverse events: myopathy, hepatotoxicity, new-onset diabetes, and drug interactions, with specific monitoring thresholds and dose-adjustment protocols.
Read clinical reviewA complete MD/PharmD-level guide to HMG-CoA reductase inhibitor pharmacology, prescribing tiers, prior-authorization strategy, and billing codes for statins used in ASCVD prevention.
Read clinical reviewA clinician-level review of statin drug-drug interactions, CYP450 metabolism, transporter-mediated DDIs, and dosing limits for every approved HMG-CoA reductase inhibitor. Includes an evidence-based interaction table with FDA-cited dose caps.
Read clinical reviewA full clinical reference on HMG-CoA reductase inhibitors (statins): mechanism, dosing, ASCVD risk stratification, lab monitoring protocols, drug interactions, and adverse effect management. Written at MD/PharmD level.
Read clinical reviewA prescriber-level monograph covering the statin drug class, including mechanism, pharmacokinetics, landmark trial data, safety profiles, drug interactions, and clinical decision-making for ASCVD prevention.
Read clinical reviewA prescriber-level guide to choosing among statins, atorvastatin, rosuvastatin, pitavastatin, and others, based on potency, drug interactions, renal function, and ASCVD risk category.
Read clinical reviewA prescriber-level guide to statin titration, tapering, dose adjustments, and switching strategies for HMG-CoA reductase inhibitors, with clinical trial evidence and guideline-based thresholds.
Read clinical review